J2G-OX-Y001 - A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507678-42-00

Acronym

LOXO-RET-18037

Enrollment

150

Registered

2024-07-16

Start date

2019-10-24

Completion date

Unknown

Last updated

2025-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

Brief summary

There are no endpoints or data analysis for this EAP trial.

Detailed description

There are no endpoints or data analysis for this EAP trial.

Interventions

DRUGSELPERCATINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
There are no endpoints or data analysis for this EAP trial.	—

Secondary

Measure	Time frame
There are no endpoints or data analysis for this EAP trial.	—

Countries

France, Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026